200 related articles for article (PubMed ID: 9164679)
1. Cytological evaluation of biological prognostic markers from primary breast carcinomas.
Makris A; Allred DC; Powles TJ; Dowsett M; Fernando IN; Trott PA; Ashley SE; Ormerod MG; Titley JC; Osborne CK
Breast Cancer Res Treat; 1997 May; 44(1):65-74. PubMed ID: 9164679
[TBL] [Abstract][Full Text] [Related]
2. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study.
Makris A; Powles TJ; Allred DC; Ashley SE; Trott PA; Ormerod MG; Titley JC; Dowsett M
Breast Cancer Res Treat; 1999 Jan; 53(1):51-9. PubMed ID: 10206072
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors.
Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Bella MA; Cocconi G
Cancer; 1999 Aug; 87(4):224-30. PubMed ID: 10455211
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas.
Nizzoli R; Bozzetti C; Naldi N; Guazzi A; Gabrielli M; Michiara M; Camisa R; Barilli A; Cocconi G
Cancer; 2000 Feb; 90(1):61-6. PubMed ID: 10692218
[TBL] [Abstract][Full Text] [Related]
5. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC
Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients.
Domanski AM; Monsef N; Domanski HA; Grabau D; Fernö M
Cytopathology; 2013 Feb; 24(1):21-5. PubMed ID: 22783929
[TBL] [Abstract][Full Text] [Related]
7. Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry.
Fernando IN; Powles TJ; Dowsett M; Ashley S; McRobert L; Titley J; Ormerod MG; Sacks N; Nicolson MC; Nash A
Virchows Arch; 1995; 426(2):155-61. PubMed ID: 7757286
[TBL] [Abstract][Full Text] [Related]
8. Biological variables in non-small cell lung cancer: comparison between immunocytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections.
Bozzetti C; Franciosi V; Crafa P; Carbognani P; Rusca M; Nizzoli R; Guazzi A; Naldi N; Cocconi G
Lung Cancer; 2000 Jul; 29(1):33-41. PubMed ID: 10880845
[TBL] [Abstract][Full Text] [Related]
9. Cytologic evaluation of cyclin D1 expression in primary breast carcinoma.
Park K; Han S; Kim HY; Ko I
Cancer; 2001 Jun; 93(3):211-5. PubMed ID: 11391609
[TBL] [Abstract][Full Text] [Related]
10. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour.
Ceccarelli C; Santini D; Chieco P; Taffurelli M; Marrano D; Mancini AM
Ann Oncol; 1995 Mar; 6(3):275-82. PubMed ID: 7612493
[TBL] [Abstract][Full Text] [Related]
11. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
Chang J; Powles TJ; Allred DC; Ashley SE; Clark GM; Makris A; Assersohn L; Gregory RK; Osborne CK; Dowsett M
J Clin Oncol; 1999 Oct; 17(10):3058-63. PubMed ID: 10506600
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
[TBL] [Abstract][Full Text] [Related]
13. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response.
Makris A; Powles TJ; Allred DC; Ashley S; Ormerod MG; Titley JC; Dowsett M
Breast Cancer Res Treat; 1998 Mar; 48(1):11-20. PubMed ID: 9541185
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of estrogen receptor immunocytochemical assay (ER-ICA) and estrogen receptor enzyme immunoassay (ER-EIA) for the determination of estrogen receptor status in breast carcinoma. A comparative study on frozen sections, cytological smears and tissue homogenates.
Szadowska A; Lasota J; Kubiak R; Graczyk G
Patol Pol; 1991; 42(1):17-23. PubMed ID: 1845477
[TBL] [Abstract][Full Text] [Related]
15. Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.
Mbonde MP; Amir H; Akslen LA; Kitinya JN
East Afr Med J; 2001 Jul; 78(7):360-5. PubMed ID: 11957260
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer.
Reiner A; Neumeister B; Spona J; Reiner G; Schemper M; Jakesz R
Cancer Res; 1990 Nov; 50(21):7057-61. PubMed ID: 2208173
[TBL] [Abstract][Full Text] [Related]
18. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors.
González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF
Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical assay of estrogen and progesterone receptors in fine needle aspirates from breast cancer patients.
Nizzoli R; Bozzetti C; Savoldi L; Manotti L; Naldi N; Camisa R; Soresi AP; Guazzi A; Cocconi G
Acta Cytol; 1994; 38(6):933-8. PubMed ID: 7992582
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
